Ara mostrant els elements 1-2 de 2
Palomeras, Sònia (Data de defensa: 2019-02-27)
The major clinical problem for HER2+ breast cancer target therapies is the acquisition of resistance. The DNA methylation status of the promoter gene region has been described as a common epigenetic ...
Rabionet Diaz, Marc (Data de defensa: 2021-11-08)
Triple negative breast cancer (TNBC) accounts for 15-20% of the breast cancers and displays an aggressive profile, poor prognosis, high relapse risk and does not have a targeted therapy. In the last ...